Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(-3.03%)
HKD 0.03
(-3.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 256.16 Million HKD | -45.28% |
| 2022 | 468.12 Million HKD | -16.55% |
| 2021 | 560.98 Million HKD | -4.18% |
| 2020 | 585.47 Million HKD | -21.91% |
| 2019 | 749.73 Million HKD | 66.91% |
| 2018 | 449.19 Million HKD | 5.21% |
| 2017 | 426.96 Million HKD | -14.32% |
| 2016 | 498.3 Million HKD | 521.64% |
| 2015 | 80.15 Million HKD | 113.72% |
| 2014 | -584.03 Million HKD | -1166.5% |
| 2013 | 54.76 Million HKD | 126.52% |
| 2012 | -206.5 Million HKD | -1037.69% |
| 2011 | 22.02 Million HKD | 113.24% |
| 2010 | -166.39 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 215.98 Million HKD | 0.0% |
| 2023 Q1 | 168.8 Million HKD | -63.94% |
| 2023 Q3 | 190.03 Million HKD | -16.72% |
| 2023 Q2 | 228.17 Million HKD | 35.17% |
| 2023 Q4 | 256.16 Million HKD | 34.8% |
| 2023 FY | 256.16 Million HKD | -45.28% |
| 2022 Q2 | 452.8 Million HKD | 18.73% |
| 2022 FY | 468.12 Million HKD | -16.55% |
| 2022 Q4 | 468.12 Million HKD | 15.78% |
| 2022 Q3 | 404.31 Million HKD | -10.71% |
| 2022 Q1 | 381.37 Million HKD | -32.02% |
| 2021 Q2 | 650.49 Million HKD | 6.36% |
| 2021 Q1 | 611.6 Million HKD | 4.46% |
| 2021 Q4 | 560.98 Million HKD | 16.6% |
| 2021 FY | 560.98 Million HKD | -4.18% |
| 2021 Q3 | 481.1 Million HKD | -26.04% |
| 2020 Q2 | 846.11 Million HKD | 10.71% |
| 2020 FY | 585.47 Million HKD | -21.91% |
| 2020 Q3 | 499.74 Million HKD | -40.94% |
| 2020 Q4 | 585.47 Million HKD | 17.15% |
| 2020 Q1 | 764.24 Million HKD | 1.93% |
| 2019 Q3 | 776.33 Million HKD | -8.71% |
| 2019 Q2 | 850.42 Million HKD | 6.43% |
| 2019 Q1 | 799 Million HKD | 77.88% |
| 2019 Q4 | 749.73 Million HKD | -3.43% |
| 2019 FY | 749.73 Million HKD | 66.91% |
| 2018 Q4 | 449.19 Million HKD | 0.23% |
| 2018 Q2 | 462.2 Million HKD | 0.22% |
| 2018 FY | 449.19 Million HKD | 5.21% |
| 2018 Q1 | 461.19 Million HKD | 8.02% |
| 2018 Q3 | 448.18 Million HKD | -3.03% |
| 2017 Q1 | 543.46 Million HKD | 9.06% |
| 2017 Q4 | 426.96 Million HKD | 0.35% |
| 2017 Q3 | 425.46 Million HKD | -21.97% |
| 2017 FY | 426.96 Million HKD | -14.32% |
| 2017 Q2 | 545.26 Million HKD | 0.33% |
| 2016 Q2 | 483.82 Million HKD | 15588.36% |
| 2016 FY | 498.3 Million HKD | 521.64% |
| 2016 Q3 | 498.3 Million HKD | 2.99% |
| 2016 Q1 | 3.08 Million HKD | -96.15% |
| 2016 Q4 | 498.3 Million HKD | 0.0% |
| 2015 Q1 | 297.42 Million HKD | 150.93% |
| 2015 Q4 | 80.15 Million HKD | 166.53% |
| 2015 Q3 | -120.47 Million HKD | -140.51% |
| 2015 Q2 | 297.42 Million HKD | 0.0% |
| 2015 FY | 80.15 Million HKD | 113.72% |
| 2014 Q4 | -584.03 Million HKD | 4.14% |
| 2014 Q3 | -609.28 Million HKD | -2177.77% |
| 2014 Q1 | 29.41 Million HKD | -46.29% |
| 2014 FY | -584.03 Million HKD | -1166.5% |
| 2014 Q2 | 29.32 Million HKD | -0.31% |
| 2013 Q2 | 18.92 Million HKD | 0.0% |
| 2013 Q4 | 54.76 Million HKD | -3.87% |
| 2013 Q3 | 56.96 Million HKD | 201.06% |
| 2013 FY | 54.76 Million HKD | 126.52% |
| 2013 Q1 | 18.92 Million HKD | 109.16% |
| 2012 Q3 | -30.16 Million HKD | -269.27% |
| 2012 Q2 | 17.81 Million HKD | 0.0% |
| 2012 Q4 | -206.5 Million HKD | -584.66% |
| 2012 FY | -206.5 Million HKD | -1037.69% |
| 2011 Q4 | 22.02 Million HKD | 0.0% |
| 2011 FY | 22.02 Million HKD | 113.24% |
| 2010 FY | -166.39 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 199.019% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 87.393% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -4209.623% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 15.047% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 1445.54% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -727.724% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 216.848% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 32.151% |
| SSY Group Limited | 1.71 Billion HKD | 85.05% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 3562.144% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 24.087% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 99.498% |